CSIMarket Company Name, Ticker, Competitors, else..
 
Clene Inc   (NASDAQ: CLNN)
 
Price: $3.8500 $-0.15 -3.750%
Day's High: $4 Week Perf: -10.05 %
Day's Low: $ 3.72 30 Day Perf: -27.9 %
Volume (M): 122,495 52 Wk High: $ 13.50
Volume (M$): $ 0 52 Wk Avg: $6.27
Open: $3.99 52 Wk Low: $3.72



 Market Capitalization (Millions $) 48
 Shares Outstanding (Millions) 12
 Employees 79
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -40
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Clene Inc is a biopharmaceutical company that focuses on the development of treatments for neurodegenerative diseases, such as multiple sclerosis and amyotrophic lateral sclerosis (ALS). They specialize in the development of nanotechnology-based therapeutics that aim to enhance the body's natural ability to repair and regenerate damaged cells in the central nervous system. Clene Inc's approach involves using their proprietary platform, known as Nanocatalysis, to develop therapeutic solutions that target underlying disease mechanisms rather than simply addressing symptoms. Their goal is to provide innovative and effective therapies that can improve the quality of life for patients suffering from neurodegenerative diseases.


   Company Address: 6550 South Millrock Drive, Suite G50 Salt Lake City 84121 UT
   Company Phone Number: 676-9695   Stock Exchange / Ticker: NASDAQ CLNN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALKS   -2.76%    
ARWR        1.68% 
AXSM        3.85% 
BMRN        2.88% 
IONS   -4.85%    
VRTX        0.82% 
• View Complete Report
   



Financing Agreement

Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility

Published Tue, Oct 1 2024 8:01 PM UTC

Clene Inc. Secures $7.3 Million Through Direct Offering and Strategic Private Placements to Bolster Financial Position Amidst Growth in Neurological Treatment MarketIn a compelling strategic move, Clene Inc. (Nasdaq: CLNN) and its wholly-owned subsidiary, Clene Nanomedicine Inc. have successfully closed on a registered direct offering and concurrent private placements that ...
Shares

Clene Inc. Enhances Financial Position with Strategic Securities Placement Amidst Recent Stock Split

Published Mon, Sep 30 2024 12:30 PM UTC

In a significant development for Clene Inc. (Nasdaq: CLNN), the company announced on September 30, 2024, that it entered into a securities purchase agreement with a healthcare-focused institutional investor. This deal entails the issuance and sale of 742,626 shares of its common stock or pre-funded warrants in lieu thereof at a price aligned with current market conditions un...
Management Announcement

Clene Inc. Prepares for Pivotal FDA Conference, Charting a Course Toward a Potential ALS Breakthrough,

Published Mon, Sep 16 2024 12:30 PM UTC

Clene Inc. Taps into Potential ALS Breakthrough with FDA In-Person Meeting on CNM-Au8 Development
In a significant development for neurodegenerative disease treatment, Clene Inc. (Nasdaq: CLNN), along with its wholly owned subsidiary Clene Nanomedicine Inc. has been granted an in-person meeting with senior leadership at the U.S. Food and Drug Administration (FDA) to dis...
Product Service News

Clene Inc. Pushes Boundaries with New Data on Promising ALS Drug Ahead of Crucial FDA Meeting

Published Tue, Aug 6 2024 12:01 PM UTC

Clene Inc. Advances ALS Treatment with Promising Phase 2 Clinical Data Submission to FDA In a significant advance in the fight against amyotrophic lateral sclerosis (ALS), Clene Inc. (Nasdaq: CLNN) reported the submission of new CNM-Au8 biomarker and clinical efficacy data to the U.S. Food and Drug Administration (FDA). This development marks another crucial step for Clene I...
Stocks on the Move

Clene Inc Shares Trail Performance, but Opportunities Arise from Recent Events

Published Fri, Jul 12 2024 11:32 AM UTC

In recent months, Clene Inc shares have been trailing the overall market performance, lacking the 18.18% growth seen across the market. This article aims to analyze the events surrounding Clene Inc and explore the implications for investors and the pharmaceutical industry. By examining recent developments, including the release of a research report, a reverse stock split ann...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 242.00
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 2
Working Capital Ratio 3.84
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.56 $
Revenues (TTM) 0.02 $
Cash Flow (TTM) -
Cash 0.78 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 2,494
Net Income per Employee (TTM) -500,228
Receivable Turnover Ratio (TTM) 9.16
Inventory Turnover Ratio (TTM) 1.25
Asset Turnover Ratio (TTM) 0.01

Profitability Ratios Current
Gross Margin (MRQ) 60 %
Operating Margin (MRQ) -5941.11 %
Net Margin (MRQ) -14915.56 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Clene Inc's Segments
Royalty Related Party    116.67 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.